140 related articles for article (PubMed ID: 30535958)
1. Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model.
Secombe KR; Ball IA; Shirren J; Wignall AD; Finnie J; Keefe D; Avogadri-Connors F; Olek E; Martin D; Moran S; Bowen JM
Cancer Chemother Pharmacol; 2019 Mar; 83(3):531-543. PubMed ID: 30535958
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
Secombe KR; Ball IA; Shirren J; Wignall AD; Keefe DM; Bowen JM
Breast Cancer; 2021 Jan; 28(1):99-109. PubMed ID: 32683606
[TBL] [Abstract][Full Text] [Related]
3. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.
Secombe KR; Ball IA; Wignall AD; Bateman E; Keefe DM; Bowen JM
Neoplasia; 2022 Aug; 30():100806. PubMed ID: 35561424
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.
Abbas R; Hug BA; Leister C; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):191-9. PubMed ID: 22418773
[TBL] [Abstract][Full Text] [Related]
6. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Chan A; Ruiz-Borrego M; Marx G; Chien AJ; Rugo HS; Brufsky A; Thirlwell M; Trudeau M; Bose R; García-Sáenz JA; Egle D; Pistilli B; Wassermann J; Cheong KA; Schnappauf B; Semsek D; Singer CF; Foruzan N; DiPrimeo D; McCulloch L; Hurvitz SA; Barcenas CH
Breast; 2023 Feb; 67():94-101. PubMed ID: 36702070
[TBL] [Abstract][Full Text] [Related]
7. The calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.
Lysyy T; Lalani AS; Olek EA; Diala I; Geibel JP
Pharmacol Res Perspect; 2019 Oct; 7(5):e00521. PubMed ID: 31523434
[TBL] [Abstract][Full Text] [Related]
8. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
[TBL] [Abstract][Full Text] [Related]
9. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
[TBL] [Abstract][Full Text] [Related]
10. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
12. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
[TBL] [Abstract][Full Text] [Related]
13. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Jacob S; Johnson M; Roque B; Quintal L; Rugo HS; Melisko M; Chien AJ
Clin Breast Cancer; 2023 Oct; 23(7):721-728. PubMed ID: 37474374
[TBL] [Abstract][Full Text] [Related]
14. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
Tiwari SR; Mishra P; Abraham J
Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
[TBL] [Abstract][Full Text] [Related]
15. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
Van Sebille YZA; Gibson RJ; Wardill HR; Secombe KR; Ball IA; Keefe DMK; Finnie JW; Bowen JM
Int J Cancer; 2017 Jun; 140(12):2820-2829. PubMed ID: 28316082
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
17. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
[TBL] [Abstract][Full Text] [Related]
18. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.
Guy M; Teixeira A; Shrier A; Meschter C; Bolognese J; Chaturvedi P
PLoS One; 2024; 19(1):e0282769. PubMed ID: 38265977
[TBL] [Abstract][Full Text] [Related]
19. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
Dhillon S
Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
[TBL] [Abstract][Full Text] [Related]
20. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
